Cirrhosis- Pipeline Insights, Recent Developments, Major Players and Review

Cirrhosis: Overview

Cirrhosis is a chronic disorder in which the liver slowly gets scarred and damaged over time. These bad scar tissues then replace existing good liver tissues, affecting the normal functioning of the liver. Cirrhosis leads to a failure of the liver as it progresses with time because it is a slow-moving condition that usually takes several years to develop. If left unchecked, scar tissue will eventually prevent the liver from functioning. Even while the liver cells survive or create new cells that are capable of producing and removing chemicals from the blood, they do not have a normal connection with the blood.

As per the findings of the National Institutes of Health, the United States finds cirrhosis disease in 1 in every 400 people. Men are more likely than women to be affected. Life expectancy in advanced cirrhosis patients usually spans from 6 months to 2 years, as it depends on factors such as the complication level of patient and availability of donors.

Report Key Takeaways

Recommended Treatment for Cirrhosis:

  • Eradication of the etiological factor

The core therapeutic strategy for all patients with aCLD is eradication of the etiological factos that causes the liver injury. At present, it is among the only successful antifibrotic approach for the target disease. In individuals with compensated cirrhosis, successful etiological treatment has been demonstrated to reduce portal hypertension, avoid decompensating, and improve outcome. However, even following etiological cure, results in patients with decompensated cirrhosis are less uniform.

  • Liver transplantation

Cirrhosis might lead your liver to stop working entirely. Liver failure is the medical term for this condition. A liver transplant treatment involves your sick liver is replaced with a healthy liver from a donor. You have the option of waiting for a deceased donor or receiving a piece of a liver from a living relative or acquaintance. However, due to a shortage of deceased-donor organs to satisfy rising demand, the waiting list for a transplant is expanding.

Recent Developments Related to Cirrhosis

  • Galecto Biotech, Inc. has made announcement regarding successful completion of their Phase 1b/2a GULLIVER-2 trial in which Part 1 was targeted by the company. The trials has evaluated the pharmacokinetics, safety, and tolerability of the oral galectin-3 inhibitor GB1211 in patients. The company has also initiated the Part 2 if this trial for the research program, which is a double-blind and 12-week randomized trial that is intended to observe the effectiveness of GB1211. The Phase 1b/2a GULLIVER-2 trial liver cirrhosis is first in the Galecto's for GB1211.
  • As per the latest recent study conducted by the some of the researchers from The Medical University of Vienna, functional magnetic resonance imaging can be act as an effective resource for finding the complications in chronic liver disease. A multidisciplinary team of researchers from the Department of Medicine III and Department of Biomedical Imaging has conducted study on different patients from the liver cirrhosis outpatient clinic of University.

Major Players Working on Cirrhosis

AstraZeneca, Encoded Therapeutics, Beam Therapeutics, Anima Biotech, Dicerna Pharmaceuticals, Cyclerion, Reveal Pharmaceuticals, Unity Biotechnology, and Alnylam Pharmaceuticals are some of the liver disease therapeutics companies.

 

Key Reasons to Purchase This Report

  • The pipeline insight’s primary objective is to provide authentic information regarding therapies and drugs that are effective for the cirrhosis patient and assess its recent results.
  • An in-depth discussion on the latest clinical practices and therapeutic trials taking place in different regions of the world, featuring the most validated data by industry experts.
  • An overview of advanced cirrhosis drugs that are under development in different stages, and shedding light on the respective companies developing the respective drugs.

Alcohol abuse, hepatitis B or C infection, primary biliary cirrhosis and bile duct disorders are some of the common causes behind the cirrhosis disease.

Individual with cirrhosis may start observing symptoms such as fatigue, itching, skin yellowing, loss of appetite, and weakness.

The healthcare expert conducts your physical examination and tailor the treatment type as per the extent of liver damage and root cause of cirrhosis.

Infections, liver failure, liver cancer, gallstones, type 2 diabetes and bone diseases gets develop in having cirrhosis.

For cirrhosis patient, it is important to completely avoid the consumption of alcohol, avoid infections, and eat low sodium diet.

Choose License Type
Published Date:  Jun 2022
Category:  Pharmaceuticals
Report ID:   60564
Report Format:   PDF
Pages:   85
Rating:    4.8 (57)
Connect With Us
+1-408-641-3282
24/7 Research Support